The US Food and Drug Administration (FDA) has approved the first-ever medication to treat Ebola virus.

In an early, phase I trial, researchers think they have found an Ebola vaccine combination that could offer at least partial protection.

The recent West African epidemic has intensified the search for an effective Ebola vaccine. And researchers are now saying they may be one step closer to finding one.

A new discovery may have given scientists a glimpse into the mechanisms behind Ebola.

The US is set to withdraw nearly all of its troops deployed to fight the Ebola outbreak in West Africa — a sign of the disease's recent slowdown. Officials cautioned, however, that the fight isn't over.

As new cases of Ebola in Liberia begin to wane, GlaxoSmithKline (GSK) has dispatched its first shipment of an experimental Ebola vaccine in an effort to put a stop to the spread of the virus.

While the Ebola epidemic in West Africa is far from over, one country is free of the virus.

The US Food and Drug Administration (FDA) today approved an Ebola test that could cut the time it takes to detect Ebola in a patient in half. This new lab test can be completed within three hours.

Researchers can safely study the highly contagious Ebola virus by following the proper safety protocol, which includes wearing a face shield. But if errors are made, those researchers may face some serious consequences.

In the fight against Ebola in West Africa, health workers are continually putting themselves at risk to treat infected patients, while pharmaceutical companies work vigorously to find an effective vaccine. Parties on both fronts have hit a stumbling block.